Good year, bad year? Two biotech CEOs hit pay dirt in 2018 as com­pen­sa­tion pack­ages swell

By any ac­count­ing mea­sure, John Oyler had a big year last year, steer­ing BeiGene to a mon­ster $903 mil­lion Hong Kong IPO, then watch­ing the stock lan­guish as the Chi­na-based biotech put its PD-1 on a track to reg­u­la­tors. But what­ev­er short­com­ings may have been in the mix at BeiGene, they didn’t pre­vent the CEO from scor­ing one of the rich­est com­pen­sa­tion pack­ages in bio­phar­ma.

In a re­cent fil­ing with the SEC BeiGene $BGNE re­vealed that the com­pa­ny founder made off with a com­pen­sa­tion deal worth $27.9 mil­lion, a big step up from the $10.3 mil­lion he snagged in 2017 and the rel­a­tive­ly mod­est $4.6 mil­lion he got for 2016 — the year BeiGene’s first IPO hit Nas­daq. 

The big stock awards he got put him as the new num­ber 2 on our pay chart, just be­hind Kare Schultz at Te­va and just ahead of John Mil­li­gan, ex-CEO at Gilead.

Xi­aobin Wu

The big­ger pack­age at the top didn’t nec­es­sar­i­ly trans­late in­to big rais­es for the rest of the team at BeiGene. CMO for hema­tol­ogy Jane Huang nailed a pack­age that was worth $3.4 mil­lion, up from $3 mil­lion the year be­fore. About the same for CMO-I/O Amy Pe­ter­son. But Oyler’s new Chi­na man­ag­er re­cruit­ed last April, Xi­aobin Wu, bagged an im­pres­sive $21.5 mil­lion, which would fall in the mid­dle of the pack for the best paid Big Phar­ma CEOs who have re­port­ed so far.

This past year is prov­ing quite a boon for biotech CEOs, where pay can vary from one year to the next. As we re­port­ed ear­li­er this week, Nick Leschly made out hand­some­ly among the rest of the field, with a com­pen­sa­tion deal that tops out at $24 mil­lion. He made $8.7 mil­lion the year be­fore.

Fur­ther spot­light­ing the bo­nan­za trend, I see that Alk­er­mes $ALKS CEO Richard Pops, who had one of the worst years in the in­dus­try, al­so man­aged to cut a big­ger slice of the ex­ec­u­tive pay pie for 2018. Dur­ing the year, we car­ried a string of re­ports on the com­pa­ny’s big pitch for a new de­pres­sion drug, which had been bur­dened by too much bad da­ta. 

The FDA nev­er tired of shoot­ing them down, de­spite the protests.

Richard Pops

Pops, it turns out, nev­er­the­less bagged a $17 mil­lion com­pen­sa­tion pack­age, up from $9.4 mil­lion. CMO Craig Hop­kin­son picked up $3.8 mil­lion.


Top im­age: John Oyler, the founder and CEO of BeiGene, at #BI­IS18, the US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit in Shang­hai on Oc­to­ber 23, 2018  End­points News, Pharm­Cube

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Scott Gottlieb, AP Images

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the helm

Right after jumping on Michael Milken’s FasterCures board on Monday, the newly departed FDA commissioner is back today with news about another life sciences board post that gives him a ringside chair to cheer on a lead player in the real-world evidence movement — one with very close ties to the FDA.

Aetion is reporting this morning that Gottlieb is joining their board, a group that includes Mohamad Makhzoumi, a general partner at New Enterprise Associates, where Gottlieb returned after stepping out of his role at the FDA 2 years after he started.

Gottlieb — one of the best connected execs in biopharma — knows this company well. As head of FDA he championed the use of real-world evidence to help guide drug developers and the agency in gaining greater efficiencies, which helped set up Aetion as a high-profile player in the game.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.